Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2006-11-30
2010-10-12
Helms, Larry R. (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C435S007100
Reexamination Certificate
active
07812124
ABSTRACT:
A method of diagnosing cancer comprising the identification of neoplastic molecular markers is disclosed. Tumor-related or neoplastic molecular markers are identified from samples taken from a subject and the molecular profile of those markers is determined. Based upon the neoplastic molecular marker profile of the subject, the tumor sub-type is ascertained and an appropriate treatment protocols initiated.
REFERENCES:
patent: 5795723 (1998-08-01), Tapscott et al.
patent: 5807522 (1998-09-01), Brown et al.
patent: 5939258 (1999-08-01), Croce et al.
patent: 6218122 (2001-04-01), Friend et al.
patent: 6333152 (2001-12-01), Vogelstein et al.
patent: 6368794 (2002-04-01), Daniel et al.
patent: 6399298 (2002-06-01), Li et al.
patent: 6440676 (2002-08-01), Kroes et al.
patent: 6838444 (2005-01-01), Zoghbi et al.
patent: 2002/0142981 (2002-10-01), Horne et al.
patent: WO 99/07725 (1999-02-01), None
patent: WO 99/44062 (1999-09-01), None
patent: WO 00/70430 (2000-11-01), None
patent: WO0121136 (2001-03-01), None
patent: WO 02/08419 (2002-01-01), None
patent: WO 02/22884 (2002-03-01), None
patent: WO 02/30268 (2002-04-01), None
patent: WO 02/081638 (2002-10-01), None
patent: WO 02/096951 (2002-12-01), None
Gure et al, Apr. 2000, PNAS, USA, 97(8): 4198-4203.
Genus et al, Sep. 2000, J Medical Genetics, 37 (Suppl 1): S40, abstract # 1.23.
Sambrook et al., 1989Molecular Cloning, A Laboratory Manual, Cold Springs Harbor Press, N.Y.
Ausubel et al., 1989Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N. Y.
Timmusk, et al.Neuron10(3), 475-489 (1993).
Palm, et al.,Brain Res. 78(1-2), 192-195 (2000).
Annex to Form PCT/ISA/206: PCT/US01/143461, Date of Mailing: Nov. 7, 2002.
Martin, K. J. et al., “Linking Gene Expression Patterns to Therapeutic Groups in Breast Cancer”,Cancer Research, American Association for Cancer Research, vol. 60, No. 8, pp. 2232-2238. Apr. 15, 2000.
Alizadeh A. A. et al., “Distinct Types of Diffuse Large B-Cell Lymphoma Identified by Gene Expression Profiling”,Nature, MacMillan Journals Ltd., vol. 403, pp. 503-512, Feb. 3, 2000.
Frohme M. et al., Use of Representational Difference Analysis and CDNA Arrays for Transcriptional Profiling of Tumor Tissue;Annals of the New York Academy of Sciences, vol. 910, pp. 85-105, 2000.
Anbazhagan, R. et al., Classification of Small Cell Lung Cancer and Pulmonary Carcinoid Bygene Expression Profiles,Cancer Research, American Association for Cancer Research, vol. 59, pp. 5119-5122, Oct. 15, 1999.
Lueking A. et al., “Protein Microarrays for Gene Expression and Antibody Screening”,Analytical Biochemistry, vol. 270, No. 1, pp. 103-111, May 1999.
Gure, A. O., et al., “Seriological Identification of Embryonic Neural Proteins as Highly Immunogenic Tumor Antigens in Small Cell Lung-Cancer”,Proceedings of the National Academy of Science, vol. 97, No. 8, pp. 4198-4203, Apr. 11, 2000.
McCormick, Mary B. et al.,“NeuroD2 and NeuroD3: Distinct Expression Patterns and Transcriptional Activation Potentials within the NeuroD Gene Family”,Molecular and Cellular Biology, vol. 16, No. 10, pp. 5792-5800.
Masai, I. et al., Midline Signals Regulate Retinal Neurogenesis in Zebrafish,Neuron, US, vol. 27, No. 2, pp. 251-263, Aug. 2000.
Brown, Nadean L. et al., “Math5 is Required for Retinal Ganglion Cell and Optic Nerve Formation”,Development, vol. 128, No. 13, pp. 2497-2508, Jul. 2001.
Database Medline (Online), Hermanson O. et al., “Expression of LMO-4 in the Central Nervous System of the Embryonic an Adult Mouse”, Database Accession No. NLM10512198XP002215211, Abstract (Jul. 1999), andCellular and Molecular Biology, vol. 45, No. 5, pp. 677-686, Jul. 1999.
Colombo, M. P. et al., “Cytokine Gene Transfer in Tumor Inhibition and Tumor Therapy: Where Are We Now”?Immunology Today, Elsevier Publications, vol. 2, No. 15, pp. 48-51, 1994.
Kononen et al., “Tissue Microarrays for High-Throughput Molecular Profiling of Tumor Specimens”,Nature Medicine, vol. 4, No. 7, pp. 844-847, Jul. 1998.
Cox, P. M. et al., “Transcription and Cancer”,British Journal of Cancer, vol. 63, No. 5, pp. 651-662.
Lee, J. E., “Basic Helix-Loop—Helix Genes in Neural Development”,Current Opinion in Neurobiology, vol. 7, No. 1, pp. 13-20, Feb. 1997.
Stockert et al.,J. Exp. Med. 1998, 187:1349-1354.
Winter, S. F. et al., “Development of Antibodies Against P53 in Lung Cancer Patients Appears Dependent on the Type of P3 Mutation”, Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75235 and National Cancer Institute/Navy Medical Oncology Branch, NIH, Bethesda, Maryland 20889.
Mudenda, B et al., “The relationship between serum Ltd3 antibodies and characteristics of human breast cancer”, Br. J. Cancer (1994)1115-1119 MacMillan Press.
Katoh et al., (Int J. Mol. Med.) 2004 14:747-751.
Palm et al. “Tracing the Neural Origins of Carcinoid Tumours May Lead to a Novel Approach to Diagnosis and Gene Therapy”, Presented in 8thInternational Conference on Gene Therapy of Cancer, Dec. 8-11, 1999, San Diego, CA.
Davis Minh-Tam
Helms Larry R.
Lorenz Todd
LandOfFree
Profiling tumor specific markers for the diagnosis and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Profiling tumor specific markers for the diagnosis and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Profiling tumor specific markers for the diagnosis and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4212436